Targeting of nuclear Factor-κB and proteasome by dithiocarbamate complexes with metals

被引:121
|
作者
Cvek, B. [1 ]
Dvorak, Z. [1 ]
机构
[1] Palacky Univ, Fac Med & Dent, Dept Med Chem & Biochem, CR-77147 Olomouc, Czech Republic
关键词
disulfiram; diethyldithiocarbamate (DDTC); pyrrolidinedithiocarbamate (PDTC); metal dithiocarbamates; NF-kappa B; proteasome; JAMM;
D O I
10.2174/138161207782110390
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dithiocarbamates and their complexes with transition metals have been used as common pesticides, vulcanizing or analytical agents for decades. These compounds are one of the most reported inhibitors of nuclear factor-kappa B (NF-kappa B) signaling cascade. Recently, it has been found that dithiocarbamates are very potent inhibitors of proteasome. NF-kappa B plays a central role in the immune system and is described as major actor in many of human cancers mainly because of its protective effects against apoptosis. Molecular mechanisms involved in regulation and function of NF-kappa B pathway have been elucidated recently. In particular, pivotal zinc containing proteins that alter NF-kappa B signal transduction were recognized, Additionally, proteasome system was found to be a key player in NF-kappa B pathway and is an attractive target for anticancer drug development Collectively, the capability of dithiocarbamates to inhibit NF-kappa B and proteasome makes these compounds promising anticancer agents. This review focuses on the biological activity of dithiocarbamate coordination compounds with regard to their possible molecular targets in NF-kappa B signaling and proteasome (JAMM domain proteins). Future research should aim to find the most suitable dithiocarbamate coordination compounds for treatment of cancer and other diseases.
引用
收藏
页码:3155 / 3167
页数:13
相关论文
共 50 条
  • [1] Combating endometriosis by blocking proteasome and nuclear factor-κB pathways
    Celik, Onder
    Hascalik, Seyma
    Elter, Koray
    Tagluk, M. E.
    Gurates, Bilgin
    Aydin, N. E.
    HUMAN REPRODUCTION, 2008, 23 (11) : 2458 - 2465
  • [2] A nuclear factor-κB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats
    Sawada, Hirofumi
    Mitani, Yoshihide
    Maruyama, Junko
    Jiang, Bao Hua
    Ikeyama, Yukiko
    Dida, Francis A.
    Yamamoto, Hatsumi
    Imanaka-Yoshida, Kyoko
    Shimpo, Hideto
    Mizoguchi, Akira
    Maruyama, Kazuo
    Komada, Yoshihiro
    CHEST, 2007, 132 (04) : 1265 - 1274
  • [3] Reply: Combating endometriosis by blocking proteasome and nuclear factor-κB pathways
    Celik, Onder
    HUMAN REPRODUCTION, 2009, 24 (11) : 2967 - 2968
  • [4] Application of the nuclear factor-κB inhibitor pyrrolidine dithiocarbamate for the treatment of endometriosis: an in vitro study
    Zhang, Jing-jing
    Xu, Zhi-ming
    Dai, Hong-ying
    Ji, Xin-qiang
    Duan, Yu-ying
    Zhang, Chun-mei
    Qin, Dong-yan
    FERTILITY AND STERILITY, 2010, 94 (07) : 2942 - 2944
  • [5] Nuclear factor-κB
    Zingarelli, B
    CRITICAL CARE MEDICINE, 2005, 33 (12) : S414 - S416
  • [6] Amelioration of experimental autoimmune uveoretinitis (EAU) with an inhibitor of nuclear factor-κB (NF-κB), pyrrolidine dithiocarbamate
    Kitamei, Hirokuni
    Iwabuchi, Kazuya
    Namba, Kenichi
    Yoshida, Kazuhiko
    Yanagawa, Yoshiki
    Kitaichi, Nobuyoshi
    Kitamura, Mizuki
    Ohno, Shigeaki
    Onoe, Kazunori
    JOURNAL OF LEUKOCYTE BIOLOGY, 2006, 79 (06) : 1193 - 1201
  • [7] Distinct roles of diverse nuclear factor-κB complexes in neuropathological mechanisms
    Pizzi, Marina
    Spano, PierFranco
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 545 (01) : 22 - 28
  • [8] Receptor activator of nuclear factor-κB ligand activates nuclear factor-κB in osteoclast precursors
    Wei, S
    Teitelbaum, SL
    Wang, MWH
    Ross, FP
    ENDOCRINOLOGY, 2001, 142 (03) : 1290 - 1295
  • [9] Inhibition of nuclear factor-κB activation by pyrrolidine dithiocarbamate prevents chronic FK506 nephropathy
    Tamada, S
    Nakatani, T
    Asai, T
    Tashiro, K
    Komiya, T
    Sumi, T
    Okamura, M
    Kim, S
    Iwao, H
    Kishimoto, T
    Yamanaka, S
    Miura, K
    KIDNEY INTERNATIONAL, 2003, 63 (01) : 306 - 314
  • [10] Nuclear factor-κB inhibition in sepsis:: Steroids versus specific nuclear factor-κb inhibitors?
    Marik, PE
    CRITICAL CARE MEDICINE, 2002, 30 (10) : 2393 - 2394